Patients in our Semaglutide program often experience steady, lasting weight loss and improved overall wellness with fewer plateaus and rebound weight gain
A potential unifying feature that enhances susceptibility among those with each of these conditions is an elevation in systemic inflammation, which leads to a greater viral load with the potential for a cytokine storm and increased mortality 3
The effect size for the model is -0.28
Hyperphagia associated with obesity is also considered a hallmark of BBS
2.4% placebo) 86.4% of participants lost at least 5% of body weight 69.1% lost at least 10% 50.5% lost at least 15% STEP 3 (Wadden et al., 2021, JAMA ): Combined with intensive behavioral therapy Average weight loss: 16.0% over 68 weeks Demonstrated that lifestyle support amplifies medication effects STEP 5 (Garvey et al., 2022, Nature Medicine ): Two-year duration study Average weight loss: 15.2% maintained over 104 weeks Demonstrated sustained effectiveness with continued use Retatrutide Clinical Trial Results Phase 2 Trial (Jastreboff et al., 2023, NEJM ): 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities Multiple dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly) Results at the 12 mg dose: Average weight loss: 24.2% in 48 weeks 100% of participants lost at least 5% of body weight 93% lost at least 10% 83% lost at least 15% 63% lost at least 20% Weight loss trajectory had not plateaued at study end Comprehensive Comparison Table Side Effects Comparison Both medications share similar gastrointestinal side effect profiles because they both activate GLP-1 receptors
